SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults admitted fir SE treatment in each of the participating centers and to identify predictors of outcome and refractoriness.

SENSE-II/AROUSE is a prospective, multicenter, non-randomized, observational registry study of consecutive cases of SE. We aimed to include university hospitals as well as non-university hospitals to enhance generalizability of the findings.

Currently, 13 high-volume medical centers in Belgium, Austria, Germany, United Kingdom, Switzerland, No common management protocol will be imposed on the participating centers. However, most institutions have established a local protocol that is closely related to the most recent guidelines for the management of SE published by the American Epilepsy Society (AES) in 2016.

We will exclude patients with anoxic status epilepticus after cardiac arrest and patients younger than 18 years.

Clinical and EEG Data will be collected prospectively from the admission of the patient to the discharge. Data collection will be performed using Research Electronic Data Capture (REDCap) electronic data capture tools hosted at Erasme Hospital in Brussels, Belgium.

To reach sufficient statistical power for multivariate analysis, a cohort size of 3000 patients is targeted.

The main objective of the study is to document patient characteristics, treatment modalities, EEG features and outcome of adults treated for SE and identify predictors of outcome. The data collected in this study could also identify gaps and opportunities for the management of this medical emergency. Lacking adequate prospective controlled trials, this will help both decision-making in clinical practice and designing future clinical trials.

Moreover, EEG data will help for a better electroencephalographic definition of SE, possible SE, and some boundary conditions, such as ictal-interictal continuum.

Inclusion Criteria:

• Patients aged 18 years or above
• Patients admitted for management of Status Epilepticus as their primary diagnosis
• Patients admitted for another primary diagnosis but identified with Status Epilepticus during their acute hospital stay

Exclusion Criteria:

- Patients with post-cardiac arrest SE

All patients of and above 18 years admitted for Status Epilepticus management or who develop Status Epilepticus during their hospital stay

All collected IPD will be shared with other researchers. not public upon reasonable request

Data will be deidentified and collected through RedCap by each local investigator.

IPD will be accessible and shared only with the researchers involved in this registry.

These de-identified data will be available for the duration of the registry and on reasonable request to Nicolas Gaspard after publication of the results.

IPD will be accessible only by the researchers involved in the building of this registry.